Literature DB >> 3791206

Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor.

Y Matuo, N Nishi, S Matsui, A A Sandberg, J T Isaacs, F Wada.   

Abstract

The rat prostate contains two types of growth factors capable of stimulating DNA synthesis in BALB/3T3 cells. These rat prostatic growth factors (RPGF) were separable by a different affinity for heparin: low affinity type RPGF and high affinity (HiA) type RPGF. About 80% of the RPGF in the cytosol from normal prostates was low affinity type, whereas more than 80% in the cytosol from the Dunning tumors was HiA type. Elution profile of HiA-RPGF showed two peaks of activity eluted from the heparin-Sepharose column, one at 1.3-1.4 M NaCl (HiA1-RPGF) and the other at 1.6-1.7 M NaCl (HiA2-RPGF). HiA2-RPGF could be purified 1100-fold from the Dunning tumor (AT-3 subline) in about 20% recovery by heparin-Sepharose chromatography. The partially purified HiA2-RPGF in the Dunning tumor has a molecular weight of about 19,000 and isoelectric point of about 3.8, and stimulated DNA synthesis at a concentration of about 0.25 nM. The activity was lost by heat treatment at 70 degrees C for 5 min and by acid treatment, whereas it was stimulated by incubating with dithiothreitol. The HiA2-RPGF did not have transforming growth factor activity at a concentration of 250 ng/ml or lower in the presence of epidermal growth factor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3791206

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Partial purification and characterization of a growth factor from human hyperplastic prostatic tissues.

Authors:  A Dignass; A W Holldorf
Journal:  Urol Res       Date:  1992

Review 2.  Morphologic and regulatory aspects of prostatic function.

Authors:  G Aumüller
Journal:  Anat Embryol (Berl)       Date:  1989

Review 3.  Bone metastasis: mechanisms and therapeutic opportunities.

Authors:  Larry J Suva; Charity Washam; Richard W Nicholas; Robert J Griffin
Journal:  Nat Rev Endocrinol       Date:  2011-01-04       Impact factor: 43.330

4.  The androgen-dependent rat prostate protein, probasin, is a heparin-binding protein that co-purifies with heparin-binding growth factor-1.

Authors:  Y Matuo; P S Adams; N Nishi; H Yasumitsu; J W Crabb; R J Matusik; W L McKeehan
Journal:  In Vitro Cell Dev Biol       Date:  1989-06

5.  Proliferation of epithelial cells derived from rat dorsolateral prostate in serum-free primary cell culture and their response to androgen.

Authors:  N Nishi; Y Matuo; T Nakamoto; F Wada
Journal:  In Vitro Cell Dev Biol       Date:  1988-08

6.  Stabilization of fibroblast growth factors by a non-cytotoxic zwitterionic detergent, 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate (CHAPS).

Authors:  Y Matuo; N Nishi; Y Muguruma; Y Yoshitake; Y Masuda; K Nishikawa; F Wada
Journal:  In Vitro Cell Dev Biol       Date:  1988-05

Review 7.  Bone metabolism and new targets for intervention.

Authors:  Bulent Akduman; E David Crawford
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

8.  Distribution of fibroblast growth factors in cultured tumor cells and their transplants.

Authors:  Y Yoshitake; K Nishikawa
Journal:  In Vitro Cell Dev Biol       Date:  1992-06

9.  Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells.

Authors:  I Sehgal; J Bailey; K Hitzemann; M R Pittelkow; N J Maihle
Journal:  Mol Biol Cell       Date:  1994-03       Impact factor: 4.138

10.  Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.

Authors:  Connie Collins; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Alan W Partin; Roberto Pili; Victoria J Sinibaldi; Janet S Walczak; Samuel R Denmeade
Journal:  Cancer Biol Ther       Date:  2007-06-05       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.